Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers in this study identified a new subpopulation of dermal fibroblasts in neonatal murine dermis marked by EGFR, which they report contributes to hair follicle regeneration through the promotion of IGF1, potentially aiding in wound-induced hair follicle neogenesis.

This article reviews the role of EGFR in human skin, focusing on the skin-related side effects of anti-EGFR cancer therapies, and reports no new clinical results.

In this study, epidermal EGFR ablation in a mouse model led to significant local and systemic inflammatory responses, highlighting EGFR's role in maintaining skin immuno-homeostasis.

This research observed that EGFR activity appears to maintain hair follicle quiescence and immune privilege, and its inhibition may lead to stem cell apoptosis and scarring alopecia during inflammation.

Inhibiting EGFR weakens skin's defense against bacteria.

This study implicates EGFR as a critical regulator of immune privilege and stem cell quiescence in hair follicles, suggesting a link between EGFR inhibition and inflammation-driven hair loss during cancer therapy.

This study found that EGFR-targeted cancer therapy can cause skin toxicities by disrupting epidermal signaling, allowing microbiota invasion and inflammation, but identified a potential treatment approach using FGF7 or SOS expression to restore barrier integrity.

This review discusses the range of cutaneous side-effects caused by EGFR inhibitors in cancer therapy and explores available treatment options, without reporting new clinical findings.

In this study, mouse models with EGFR deficiency showed that disrupted hair follicle cycling leads to increased mast cell numbers and inflammation, suggesting EGFR's role in managing hair cycle transitions and preventing folliculitis.

EGFR helps protect hair follicles from bacterial infections.

In this study, mice engineered to express human EGFR showed tissue-specific growth defects and neurodegeneration rescue, but developed severe heart issues and accelerated bone cell differentiation.

In this report, two cases of non-small cell lung cancer treated with gefitinib showed unexpected hair growth, suggesting a potential new application of EGFR-TKIs for alopecia.

This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.

This review discusses the effects of the epidermal growth factor receptor system on skin biology and pathology, relying on animal models to analyze roles in cellular processes, wound healing, and tumorigenesis, but reports no new results.

Light and temperature affect the daily skin function rhythms in hairless rats, with temperature influencing water loss but not skin hydration.

This study explores how EGFR signaling impacts skin inflammation and follicular integrity during hair eruption, aiming to identify druggable pathways to mitigate skin inflammation in cancer patients receiving EGFR inhibitors.

This review discusses the role of the EGF receptor/ligand system in skin homeostasis and its implications for keratinocyte stem cells and reports no new clinical results.

This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.

This article discusses the common cutaneous side effects associated with EGFR inhibitors, emphasizing the importance of their management due to potential impacts on patients' quality of life and therapy response; no new empirical findings are reported.

In this study, Waved-5 mice with reduced EGFR signaling showed nearly normal skin and hair follicle function but experienced a transient reduction in subcutaneous fat.

In this study, EREG promoted hair growth by activating specific receptors in cell and animal models, indicating it may be a potential treatment for hair loss.

This review summarizes adverse events associated with EGFR-targeting cancer therapies, such as skin rashes and lung disease, and reports no new clinical results.

This study reported that EGFR activation leads to suppression of Stathmin, which may promote synchronized entry into catagen in hair follicles, highlighting potential mechanisms involving EGFR in hair cycle transitions.

In this study, disrupting the epidermal growth factor receptor in mice led to abnormal hair and skin development, characterized by disorganized hair follicles and systemic disease, providing a model for understanding EGFR's role in skin biology.

This study found that EGFR signaling modulates GLI target gene expression, potentially influencing outer root sheath cell specification and hair growth, and may have implications for cancer.

This study reported that in mouse models, deletion of EGFR resulted in stem cell hyper-proliferation followed by apoptosis, leading to scarring alopecia, and implicated EGFR's role in maintaining hair follicle quiescence and immune privilege during inflammation.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

This study in mice found that a monoclonal antibody targeting EGFR resulted in skin inflammation mediated by TNFα, suggesting potential pathways for addressing EGFR antibody-induced skin rash in cancer patients.

This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.

EGFR signaling is essential for ear cell regeneration in both birds and mammals.